Extended-release ketamine tablets offer new hope for treatment-resistant depression

FHS
June 26, 2024
4:17 am

The BEDROC trial found that extended-release ketamine tablets (R-107) significantly improve depressive symptoms in treatment-resistant depression patients, with the 180 mg dose showing the most efficacy. The treatment was well-tolerated with minimal side effects.

MedPod Deep Dive: More Problems With For-Profit Nursing Schools

The following is a transcript of the podcast episode: Rachael Robertson: Hey everybody. Welcome to MedPod Today, the podcast series where MedPage Today reporters share

April 23, 2024

Pumpkin Safety Tips; Sleep MD Snoozing Tricks; What It’s Like to Date a Resident

The following contains links to social media websites including X, TikTok, Instagram, Facebook, and LinkedIn. It’s pumpkin patch season, which means … potential back injuries?

October 18, 2024

When should marijuana use deny a patient an organ transplant?

In 2023, Kentucky became the most recent state to pass a law prohibiting the denial of organ transplantation to patients solely because of their marijuana

October 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.